| Name | Title | Contact Details |
|---|
The future of medical image management is in the cloud. Unfortunately, the farther data travels the more lag time accrues. We call this latency. Radiologists and other physicians are accustomed to receiving images at rates of 50 frames per second. When traveling across the entire United States, it may drop to 10 frames per second - much too slow for acceptable patient care. NucleusHealth™ overcomes latency via our patent-pending streaming protocols, client-side rendering techniques, modern web browser technologies, and the computing horsepower of todays phones, laptops and desktops. Diagnostic quality images come to life on displays at blazing-fast speeds. Even large file types such as digital breast tomosynthesis can be displayed in seconds, not minutes. With that single achievement, NucleusHealth sets a new standard for performance, scalability, security, high availability and response times. Faster, more accurate care means better outcomes at a lower cost. The next generation of medical image management has been born.
Transitional Living and Community Support is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Midwest Health Plan is committed to providing excellence in managed care product lines to the residents of the State of Michigan, through fiscally responsible programs that assure access to and the delivery of cost effective/quality medical services.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.